Exemestane significantly reduced invasive breast cancers in postmenopausal women who were at moderately increased risk for breast cancer Background Tamoxifen and raloxifene have limited patient acceptance for primary prevention of breast cancer. Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effects than tamoxifen in patients with early-stage breast cancer.